Assess whether scientific advice should be sought before the next trial

SITUATION Labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT has one working extract — 505(b)(2) literature-to-product bridge table — after a DSMB note on an imbalance that is not yet a signal. If 505(b)(2) literature-to-product bridge table cannot support scientific advice should be, the only defensible Pharma & Life Sciences output is hold.

DECISION Labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after a DSMB note on an imbalance that is not yet a signal.

HYPOTHESES TO TEST 1. Labeling negotiator can defend Proceed under protocol from 505(b)(2) literature-to-product bridge table after a DSMB note on an imbalance that is not yet a signal in a Pharma & Life Sciences challenge. 2. Labeling negotiator cannot defend Proceed under protocol from 505(b)(2) literature-to-product bridge table; Pause the pathway is what the extract actually supports after a DSMB note on an imbalance that is not yet a signal. 3. A DSMB note on an imbalance that is not yet a signal never reached the population in 505(b)(2) literature-to-product bridge table — reopen intake, do not close scientific advice should be. 4. Two facts in 505(b)(2) literature-to-product bridge table after a DSMB note on an imbalance that is not yet a signal conflict for labeling negotiator; hold this Clinical and Evidence Strategy file.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a DSMB note on an imbalance that is not yet a signal. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on scientific advice should be. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read 505(b)(2) literature-to-product bridge table against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move scientific advice should be for labeling negotiator.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (505(b)(2) literature-to-product bridge table after a DSMB note on an imbalance that is not yet a signal). The follow-on Clinical and Evidence Strategy action is what labeling negotiator does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on scientific advice should be, then the evidence in 505(b)(2) literature-to-product bridge table, then the action for labeling negotiator - Hypothesis scorecard against 505(b)(2) literature-to-product bridge table: supported / rejected / untestable - Clinical and Evidence Strategy finding in 505(b)(2) literature-to-product bridge table that a second reviewer can re-perform - Missing page in 505(b)(2) literature-to-product bridge table after a DSMB note on an imbalance that is not yet a signal, if any